Clopidogrel

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Clopidogrel

Examples of brand names: Plavix [EU/DE]

ATC code: B01AC04

Main use (for orientation): Platelet inhibition

Documented research summary

CBD inhibition of CYP2C19 and the Epidiolex warning support a potential loss of efficacy, not a clinically confirmed loss. The geriatric case includes precautionary discontinuation of CBD, no measured change in active metabolite/platelets, and does not prove that CBD caused an infarction.

Uncertainties and limitations

No quantitative CBD-pair study or established dose–response threshold.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – theoretical plausibility

Finding ID: B0007

Type of result: Untested clinical possibility

Observation: Reduced formation of active metabolite is possible.

Mechanism: CYP2C19 inhibition; prodrug activation

Study type: Regulatory mechanistic warning

Context studied: No direct human study of the pair in this source.

Clinical interpretation: Potentially high relevance, pair clinically unquantified

Limitations and uncertainties: Do not infer an established thrombosis rate.

Original sources for this finding: EPIDIOLEX (cannabidiol) oral solution – US Prescribing Information, revised 5/2026 [V5_US_LABEL_2026]; EPIDIOLEX (cannabidiol) oral solution – Prescribing Information, revised 6/2025 [CL02]

References and access status

[CA_L_D0008] CLOPIDOGREL (CLOPIDOGREL BISULFATE) TABLET, FILM COATED [APOTEX CORP.]

Original source / bibliographic reference

Authors: Apotex Corp.

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL02] EPIDIOLEX (cannabidiol) oral solution – Prescribing Information, revised 6/2025

Original source / bibliographic reference

Authors: FDA / Jazz Pharmaceuticals

Year: 2025

Source type: Regulatory product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_36949558] Geriatric Pharmacotherapy Case Series: Potential Drug Interactions With Antiplatelet Medications and Cannabidiol-A Focus on P2Y12 Inhibitors.

Original source / bibliographic reference

Authors: Brown SA, Boyd K, Thomason AR.

Year: 2023

Source type: Journal Article; Case Reports

DOI: 10.4140/tcp.n.2023.141

PMID: 36949558

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[V5_US_LABEL_2026] EPIDIOLEX (cannabidiol) oral solution – US Prescribing Information, revised 5/2026

Original source / bibliographic reference

Authors: Jazz Pharmaceuticals, Inc. / DailyMed

Year: 2026

Source type: Regulatory US product information; not an additional independent clinical study

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility